Is your organization ready for the implementation of European Joint Clinical Assessments of health technologies? Are you keen to understand and navigate the potential impact on your pipeline assets?
European Joint Clinical Assessments may present new challenges for your organization
In 2025, joint clinical assessments (JCA) of new advanced therapy medicinal products (ATMPs) and oncology medicines will commence. While not legally binding, these will affect national health technology assessments (HTAs) and may present new challenges for your organization.
How ready is your organization to:
- Understand the process and impact of the Population, Intervention, Comparator(s), Outcomes (PICO) scoping at EU and market level
- Generate robust evidence to meet market-level vs consolidated PICO-level requirements
- Differentiate between market level issues and JCA outcomes to refine market-level strategy
- Manage uncertainty regarding implementation of JCA in practice and the impact on HTA and pricing decisions?
Avalere Health will help you prepare for JCA. We are experienced in early scientific advice, EUnetHTA submissions, and EMA-EUnetHTA 21 Joint Scientific Consultations and have an in-depth understanding of market access and HTA.
Please download our case studies and insights from ISPOR 2023 to find out how we can help you map out your JCA strategic and tactical initiatives for the remainder of the year and beyond.